Serum levels of cell adhesion molecules in patients with neuromyelitis optica spectrum disorder.
Journal
Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
26
02
2020
revised:
09
07
2020
accepted:
04
08
2020
pubmed:
30
8
2020
medline:
18
8
2021
entrez:
30
8
2020
Statut:
ppublish
Résumé
Blood-brain barrier (BBB) disruption is a critical pathological process involved in neuromyelitis optica spectrum disorder (NMOSD). Here, we characterized the profile of five cell adhesion molecules in patients with NMOSD. We measured levels of cell adhesion molecules, including ICAM-1, ICAM-2, VCAM-1, PECAM-1, and NCAM-1, in the serum of 28 patients with NMOSD, 24 patients with multiple sclerosis (MS), and 25 healthy controls (HCs). ICAM-2 levels (median: 394.8 ng/mL) were increased in patients with NMOSD compared with MS (267.1 ng/mL, P = 0.005) and HCs (257.4 ng/mL, P = 0.007), and VCAM-1 and ICAM-1 levels were higher in patients with NMOSD (641.9 ng/mL and 212.7 ng/mL, respectively) compared with HCs (465 ng/mL [P = 0.013] and 141.8 ng/mL [P = 0.002], respectively). However, serum PECAM-1 levels were lower in patients with NMOSD (89.62 ng/mL) compared with MS (106.9 ng/mL, P = 0.015) and HCs (107.2 ng/mL, P = 0.007). Receiver operating characteristic curve analysis revealed that PECAM-1 (area under the curve (AUC): 0.729) and ICAM-2 (AUC: 0.747) had adequate abilities to distinguish NMOSD from MS, and VCAM-1 (AUC: 0.719), PECAM-1 (area under the curve: 0.743), ICAM-1 (AUC: 0.778), and ICAM-2 (AUC: 0.749) exhibited potential to differentiate NMOSD and HCs. Serum levels of PECAM-1 also demonstrated a negative correlation with Kurtzke Expanded Disability Status Scale scores in patients with NMOSD. Our results reveal possible BBB breakdown signals specifically observed in NMOSD and highlight the potential role of cell adhesion molecules as biomarkers of this disease.
Identifiants
pubmed: 32860355
doi: 10.1002/acn3.51167
pmc: PMC7545585
doi:
Substances chimiques
Biomarkers
0
Vascular Cell Adhesion Molecule-1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1854-1861Informations de copyright
© 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
J Neuroimmunol. 2016 Nov 15;300:11-14
pubmed: 27806869
J Neuroimmunol. 2005 Oct;167(1-2):143-9
pubmed: 16040131
Curr Opin Hematol. 2015 Jan;22(1):53-9
pubmed: 25427141
Eur J Neurol. 2006 Dec;13(12):1284-90
pubmed: 17116209
J Neurol. 2012 May;259(5):801-16
pubmed: 21932127
J Immunol. 2002 Jun 15;168(12):6455-62
pubmed: 12055265
Brain. 2007 May;130(Pt 5):1194-205
pubmed: 17282996
J Exp Med. 1991 Jul 1;174(1):253-67
pubmed: 1676048
J Exp Med. 1993 Aug 1;178(2):449-60
pubmed: 8340753
J Neurol Sci. 2019 Jan 15;396:36-41
pubmed: 30412901
Nature. 2005 Sep 15;437(7057):426-31
pubmed: 16163360
Mult Scler Relat Disord. 2020 Jan;37:101452
pubmed: 31670010
Am J Physiol Heart Circ Physiol. 2005 Jan;288(1):H159-64
pubmed: 15319204
J Cell Sci. 2014 Feb 1;127(Pt 3):620-9
pubmed: 24317296
Curr Opin Hematol. 2016 May;23(3):253-9
pubmed: 27055047
Nature. 2003 Feb 13;421(6924):748-53
pubmed: 12610627
Front Immunol. 2019 Apr 05;10:711
pubmed: 31024547
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Nature. 2012 Aug 16;488(7411):399-403
pubmed: 22763437
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
Folia Morphol (Warsz). 2002;61(3):143-5
pubmed: 12416929
Brain. 2002 Jul;125(Pt 7):1450-61
pubmed: 12076996
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Transfus Clin Biol. 2008 Feb-Mar;15(1-2):3-6
pubmed: 18501655
Brain. 2007 May;130(Pt 5):1224-34
pubmed: 17405762
Life Sci. 2010 Jul 17;87(3-4):69-82
pubmed: 20541560
J Neuroimmunol. 1999 Oct 29;99(2):169-72
pubmed: 10505971
Lancet Neurol. 2012 Jun;11(6):535-44
pubmed: 22608667
Am J Pathol. 2005 Jan;166(1):185-96
pubmed: 15632011
J Neurol. 2011 Dec;258(12):2176-80
pubmed: 21594697
Immunol Med. 2018 Sep;41(3):120-128
pubmed: 30938273
Eur Rev Med Pharmacol Sci. 2009 Sep-Oct;13(5):397-9
pubmed: 19961048
Ann Neurol. 1997 Mar;41(3):326-33
pubmed: 9066353
Neurol Neuroimmunol Neuroinflamm. 2015 Jul 23;2(4):e134
pubmed: 26236760
Am J Physiol Cell Physiol. 2019 Feb 1;316(2):C135-C153
pubmed: 30379577
Mult Scler. 1998 Jun;4(3):178-82
pubmed: 9762670
Acta Neuropathol. 2010 Aug;120(2):223-36
pubmed: 20532539
Arch Neurol. 2011 Jul;68(7):913-7
pubmed: 21747031
Neurobiol Dis. 2015 Feb;74:14-24
pubmed: 25448765
J Exp Med. 2014 Jun 30;211(7):1307-14
pubmed: 24913232
Dis Markers. 2006;22(4):235-44
pubmed: 17124345
J Immunol. 2007 Dec 1;179(11):7344-51
pubmed: 18025177
Arch Med Res. 2014 Nov;45(8):687-97
pubmed: 25431839
J Immunol. 1999 Jul 15;163(2):682-8
pubmed: 10395658
Ann Neurol. 2009 Nov;66(5):630-43
pubmed: 19937948